Compare SCD & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | TXG |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.0M | 2.8B |
| IPO Year | N/A | 2019 |
| Metric | SCD | TXG |
|---|---|---|
| Price | $16.13 | $17.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $16.18 |
| AVG Volume (30 Days) | 62.6K | ★ 2.6M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $642,823,000.00 |
| Revenue This Year | N/A | $5.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.25 |
| 52 Week Low | $11.33 | $6.78 |
| 52 Week High | $15.87 | $23.56 |
| Indicator | SCD | TXG |
|---|---|---|
| Relative Strength Index (RSI) | 68.97 | 52.14 |
| Support Level | $15.48 | $17.26 |
| Resistance Level | $16.00 | $19.43 |
| Average True Range (ATR) | 0.16 | 1.17 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 91.23 | 50.08 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).